Equities

Ondine Biomedical Inc

OBI:LSE

Ondine Biomedical Inc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.00
  • Today's Change0.00 / 0.00%
  • Shares traded42.16k
  • 1 Year change-28.00%
  • Beta0.4964
Data delayed at least 20 minutes, as of Feb 06 2026 12:53 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Ondine Biomedical Inc had net income fall 32.51% from a loss of 14.41m to a larger loss of 19.10m despite a 70.32% increase in revenues from 1.20m to 2.05m.
Gross margin65.77%
Net profit margin-1,084.66%
Operating margin-1,095.51%
Return on assets-373.83%
Return on equity-6,414.77%
Return on investment-4,807.85%
More ▼

Cash flow in CADView more

In 2024, Ondine Biomedical Inc increased its cash reserves by 216.32%, or 6.79m. Cash Flow from Financing totalled 21.74m or 1,060.86% of revenues. In addition the company used 15.49m for operations while cash used for investing totalled 10.00k.
Cash flow per share-0.0336
Price/Cash flow per share--
Book value per share0.0009
Tangible book value per share0.0009
More ▼

Balance sheet in CADView more

Ondine Biomedical Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio0.9651
Quick ratio0.7948
Total debt/total equity0.7645
Total debt/total capital0.4333
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.